Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Improvement to formulation

<< Previous

Bullboard Posts

Next >>

Comment by Danorrnon Aug 30, 2021 7:49am

235 Views

Post# 33780662

RE:Improvement to formulation

I like this actually..."And it is ironic (unfortunately so) that if otenaproxesul is withdrawn, it would be because of toxicity typical of Tylenol rather than that of traditional NSAIDs." Toxicity typical of tylenol. Why would they withdraw if it is typical of a drug already in use? Surely you know how much tylenol is used internationally and how much cash that represents?

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario